Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Feb 2011

Klümpen Heinz-Josef, Queiroz Karla C S, Spek C Arnold, van Noesel Carel J M, Brink Helmy C, de Leng Wendy W J, de Wilde Roeland F, Mathus-Vliegen Elisabeth M H, Offerhaus G Johan A, Alleman Maarten A, Westermann Anneke M, Richel Dirk J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Antineoplastic Agents
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pancreatic Neoplasms

Share to Peutz-Jeghers Syndrome

Share to Protein Serine-Threonine Kinases

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 21189378
DOI: 10.1200/JCO.2010.32.7825
PMCID: PMC4856022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.PMID 21189378Read ↗

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic DiseasesSemantic proximity Read ↗

Targeting Notch signaling in pancreatic cancer patients - rationale for new therapySemantic proximity Read ↗

Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned.Semantic proximity Read ↗

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.Semantic proximity Read ↗

Targeting mTOR in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.Semantic proximity Read ↗

MTOR inhibitor-based combination therapies for pancreatic cancerSemantic proximity Read ↗

Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin PathwaySemantic proximity Read ↗

K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules.Semantic proximity Read ↗

Targeting mTOR dependency in pancreatic cancer.Semantic proximity Read ↗

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complexSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.